How Cannabis Impacts Health & the Potential Risks | Dr. Matthew Hill

How Cannabis Impacts Health & the Potential Risks

Summary

Dr. Matthew Hill, a professor at the University of Calgary’s Hotchkiss Brain Institute, joins Andrew Huberman to discuss the biology of cannabis in depth. The conversation covers how THC interacts with the brain’s endocannabinoid system, the mechanisms behind psychoactive effects, appetite stimulation, memory, and the relationship between cannabis use and mental health. This episode was prompted by Dr. Hill’s public criticism of claims made in a previous Huberman Lab solo episode on cannabis.

---

Key Takeaways

• THC is not a sledgehammer — it is actually a partial agonist at CB1 receptors with high affinity but relatively low efficacy, similar to anandamide, not a supercharged version of the body’s own cannabinoids
• Cannabis “carpet bombs” the entire endocannabinoid system — unlike endogenous cannabinoids that act precisely at specific synapses and times, THC floods all CB1 receptors simultaneously, which is what produces intoxication
• Blocking anandamide breakdown does NOT produce a high — drugs that elevate anandamide by inhibiting its metabolic enzyme (FAAH inhibitors) show no psychoactivity, suggesting THC’s effects come from its indiscriminate, whole-brain receptor activation
• The “munchies” involve overriding satiety signals — cannabis reactivates appetite even in fully satiated animals by maintaining the reward value of food and blocking leptin’s anorectic effects
• Dopamine neurons are the one exception — CB1 receptors are found nearly everywhere in the brain except on dopamine neurons; cannabis influences dopamine indirectly by disinhibiting inhibitory neurons
• Edibles and inhaled cannabis are fundamentally different — the two routes produce very different pharmacokinetic profiles, onset times, and subjective experiences
• Regular users self-titrate effectively — even with higher-potency modern cannabis (20–30% THC), experienced users achieve similar blood THC levels (~100 ng/mL) as those using lower-potency products
• Short-term memory impairment during intoxication is well-established, but long-term cognitive deficits in regular users are not clearly supported by current evidence

---

Detailed Notes

What Is Cannabis?

• Cannabis is a plant with a long history of medicinal, spiritual, and recreational use across cultures
• The primary psychoactive compound is Delta-9-tetrahydrocannabinol (THC) — the higher the THC concentration, the more intense the intoxication
• Cannabidiol (CBD) is structurally similar to THC but is non-intoxicating; may have some psychoactive properties through effects on anxiety or mood
• 70+ minor cannabinoids exist in the plant (e.g., cannabinol, cannabigerol); their biology is largely unknown
• Terpenes (e.g., limonene, pinene, beta-caryophyllene, myrcene) are volatile aromatic compounds, not unique to cannabis; some have known biological activity
• The “entourage effect” refers to the idea that the combination of THC, minor cannabinoids, and terpenes produces different effects than isolated THC — this remains under active investigation

The Endocannabinoid System

• The brain’s primary cannabis-sensitive receptor is CB1 (cannabinoid type 1 receptor) — one of the most widely expressed receptors in the entire brain
• CB2 receptors are found mainly on immune cells (microglia) and regulate inflammation; minimal expression in neurons
• Neither receptor evolved for cannabis — they exist for the body’s own endocannabinoid system

Retrograde Signaling:

• Unlike most neurotransmitters (which travel forward, neuron A → neuron B), endocannabinoids are made in the postsynaptic neuron (B) and travel backward to regulate neurotransmitter release from the presynaptic neuron (A)
• Primary function: homeostasis — preventing runaway excitation (seizure-like states) or runaway inhibition

Two Primary Endocannabinoids:

• Anandamide — named from Sanskrit ananda (bliss); high affinity, low efficacy at CB1; thought to be tonic (steady-state regulator, like a thermostat)
• 2-Arachidonoylglycerol (2-AG) — lower affinity, higher efficacy; thought to be phasic (brought online on demand, especially during high neural activity or plasticity events)

How THC Differs from Endocannabinoids

• THC is a partial agonist at CB1 — similar affinity and efficacy to anandamide, not dramatically stronger
• The critical difference: endocannabinoids act at specific synapses at specific times; THC distributes throughout the bloodstream and activates CB1 receptors indiscriminately across all brain networks simultaneously
• This blanket activation — especially across cortical circuits — disrupts normal information processing and produces the intoxicated state
• FAAH inhibitors (drugs that block anandamide breakdown) confirm this: dramatically elevating anandamide produces no psychoactivity, demonstrating that THC’s intoxication is not simply about receptor activation level but about spatial and temporal indiscrimination

Cannabis, Dopamine, and Euphoria

• Dopamine neurons are notably absent of CB1 receptors — the only major neuron class in the brain that lacks them
• Cannabis influences dopamine indirectly: CB1 receptors on inhibitory neurons surrounding dopamine neurons in the ventral tegmental area (VTA) are activated by THC, removing inhibition and allowing dopamine neurons to burst-fire
• This mechanism parallels how mu-opioid receptors work with opioids
• Whether this dopamine release directly causes the euphoria of cannabis has not been cleanly demonstrated

Cannabis and Appetite (“The Munchies”)

• Cannabis stimulates appetite through multiple convergent mechanisms:
  1. Disinhibition of AgRP neurons in the hypothalamus (hypothalamic feeding circuits rich in CB1 receptors)
  2. Reward circuit engagement — anandamide in the nucleus accumbens enhances intake of palatable foods
  3. Enhanced gustatory processing — CB1 activation selectively amplifies sweet taste responses in the gustatory cortex (not salty, bitter, or sour)
• THC may trick the brain into a fasted state — endocannabinoids naturally rise during fasting to promote food seeking; THC activates those same circuits regardless of actual energy state
• Satiety override: Animals pre-satiated (or conditioned to avoid food via nausea) will re-initiate eating and even perform high levels of work (lever pressing) for food when given cannabis
• Leptin blockade: THC can override leptin signaling — normally, leptin suppresses endocannabinoid activity to reduce food intake; cannabinoid elevation reverses this

Cannabis and Memory

• Acute intoxication reliably impairs short-term memory — particularly recall and consolidation; well-supported by both animal and human research
• Long-term cognitive deficits in regular users are not clearly established — evidence is not consistently replicated or reliable
• State-dependent learning is a confound: chronic users who have repeatedly performed cognitive tasks while intoxicated may show less impairment when tested high, not because cannabis enhances cognition but because of adaptation
• Regular users tend to show less acute memory impairment than occasional users, likely due to tolerance or state-dependent habituation

Routes of Administration: Inhaled vs. Edibles

• Inhaled cannabis: Rapid onset (approximately 2–5 minutes to subjective effects); users can titrate dose effectively based on rapid feedback
• Edible cannabis: Fundamentally different pharmacokinetics — slower onset, delayed and often more intense and prolonged effects; much harder to titrate
• THC potency increase: Modern commercial cannabis typically runs 20–30% THC vs. ~5% in 1970s cannabis — roughly analogous to moving from beer/wine to spirits
• Despite higher-potency products, experienced users still achieve similar blood THC levels (~100 ng/mL) through self-titration — except with concentrates (dabs), where blood